

Understanding Advanced HIV Disease Demand Generation

Mr. Fred Chungu

Network of Zambian People Living with HIV

CQUIN 6th Annual Meeting

December 6 – 9, 2022 | Durban, South Africa



Outline

1. Framing remarks
2. AHD Video
3. Panel Discussions

Framing Remarks



Objectives

- To address critical gaps in understanding AHD service delivery among RoC
- To determine the best strategic approaches to scale up AHD advocacy within the CQUIN CAN member countries

Background and rationale

- A significant proportion of patients continue to present with advanced HIV disease
- People starting ART with advanced HIV disease have high mortality particularly in the first six months following ART initiation
- Major causes of death include co-infections such as TB, severe bacterial infections, and cryptococcal meningitis
- WHO guidelines include individual recommendations for diagnosis, prophylaxis and treatment
- Recent studies have assessed the potential for an enhanced package of interventions to reduce mortality/morbidity which are being adapted by CQUIN member countries

WHO Recommendation

A package of interventions including screening, treatment and/or prophylaxis for major opportunistic infections, rapid ART initiation* and intensified adherence support interventions should be offered to everyone presenting with advanced HIV disease.

Strong recommendation, moderate-quality evidence

* linked recommendation

Role of Civil Society Organizations

- Civil society organizations and communities should be **continuously engaged** by countries, funders and WHO in all decision-making processes
- Global health funders should **support HIV CSOs with funding** to enable them to better hold stakeholders to account to remove access barriers to screening and treatment of cryptococcal meningitis

Role of Civil Society Organizations

- Civil society organizations and communities should **increase awareness, create demand, monitor** availability of and access to L-AmB access at facility levels.
- Civil society organizations should **integrate into their advocacy work** not only HIV, but also advanced HIV disease, cryptococcal meningitis and access barriers to WHO-recommended treatments including L-AmB and flucytosine

AHD Advocacy Resources



Links to Additional Resources

CHAI website with AHD resources:

- AHD Social Media Campaign resources developed by Community Advisory Board (CAB) members:

<https://www.newhivdrugs.org/post/ahd-social-media-campaign>

- AHD Community Advocacy Video developed by Community Advisory Board (CAB) members:

<https://www.newhivdrugs.org/post/ahd-community-advocacy-video>

[Play video]

Panel Discussion



AHD Panel Discussion

- Nelson Otwoma, NEPHAK, Kenya
- Lindiwe Similane, SASO, Eswatini
- Nkechi Okoro, NEPHWAN, Nigeria

Thank you!

